Multi-omics Analysis Identifies UBA Family As Potential Pan-cancer Biomarkers for Tumor Prognosis and Immune Microenvironment Infiltration

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Mar 6

PMID 40046044

Authors

Haibin Wang

Xinli Liu

Hesen Huang

Meng Tang

Jiwei Li

Tingting Huang

Shengjie Wang

Affiliations

Soon will be listed here.

Abstract

Background: UBA1 and UBA6 are classic ubiquitin-activating E1 enzymes, which participate in the ubiquitination degradation of intracellular proteins and are closely related to the occurrence and development of various diseases and tumors. However, at present, comprehensive analysis has not been used to study the role of UBA family in cancers.

Methods: We extracted the relevant data of cancer patients from the TCGA database and studied the relationship between the expression patterns of UBA family and the survival rate, and stage of patients in pan-cancer, especially breast cancer (BRCA), colorectal cancer (COAD), renal cancer (KIRC) and lung adenocarcinoma (LUAD). In addition, we also evaluated their impact on immune infiltration using TISIDB database and R packages.

Results: UBA1 and UBA6 are highly expressed in most cancer types, which may be associated with poor prognosis of patients. This study also investigated their expression had a closely tie with clinical stages in some specific tumors. Furthermore, this study also demonstrated that these genes were closely related to immune score, immune subtypes and tumor infiltrating immune cells.

Conclusions: Our study demonstrated that the differential expression of the UBA family, along with their associated survival landscape and immune infiltration across various cancer types, holds potential as biomarkers linked to cancer immune infiltration. This finding offers a novel perspective for informing the direction of cancer treatment strategies.

References

Jin J, Li X, Gygi S, Harper J . Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature. 2007; 447(7148):1135-8. DOI: 10.1038/nature05902. View

Zhang Y, Qian H, Wu B, You S, Wu S, Lu S . E3 Ubiquitin ligase NEDD4 family‑regulatory network in cardiovascular disease. Int J Biol Sci. 2020; 16(14):2727-2740. PMC: 7586430. DOI: 10.7150/ijbs.48437. View

Inui N, Sakai S, Kitagawa M . Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway. Int J Mol Sci. 2021; 22(11). PMC: 8201174. DOI: 10.3390/ijms22116107. View

Dagogo-Jack I, Shaw A . Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2017; 15(2):81-94. DOI: 10.1038/nrclinonc.2017.166. View

Popovic D, Vucic D, Dikic I . Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014; 20(11):1242-53. DOI: 10.1038/nm.3739. View

Labrie M, Brugge J, Mills G, Zervantonakis I . Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022; 22(6):323-339. PMC: 9149051. DOI: 10.1038/s41568-022-00454-5. View

Shan Y, Yang G, Huang H, Zhou Y, Hu X, Lu Q . Ubiquitin-Like Modifier Activating Enzyme 1 as a Novel Diagnostic and Prognostic Indicator That Correlates With Ferroptosis and the Malignant Phenotypes of Liver Cancer Cells. Front Oncol. 2020; 10:592413. PMC: 7744729. DOI: 10.3389/fonc.2020.592413. View

McBride A, Ryan P . Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013; 13(3):339-58. DOI: 10.1586/era.13.9. View

Reinhold W, Sunshine M, Varma S, Doroshow J, Pommier Y . Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res. 2015; 21(17):3841-52. PMC: 4558215. DOI: 10.1158/1078-0432.CCR-15-0335. View

10.

Moudry P, Lukas C, Macurek L, Hanzlikova H, Hodny Z, Lukas J . Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle. 2012; 11(8):1573-82. DOI: 10.4161/cc.19978. View

11.

Shen J, Fu B, Li Y, Wu Y, Sang H, Zhang H . E3 Ubiquitin Ligase-Mediated Regulation of Osteoblast Differentiation and Bone Formation. Front Cell Dev Biol. 2021; 9:706395. PMC: 8430030. DOI: 10.3389/fcell.2021.706395. View

12.

Chen W, Dai X, Chen Y, Tian F, Zhang Y, Zhang Q . Significance of STAT3 in Immune Infiltration and Drug Response in Cancer. Biomolecules. 2020; 10(6). PMC: 7355836. DOI: 10.3390/biom10060834. View

13.

Bulatov E, Valiullina A, Sayarova R, Rizvanov A . Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases. Immunol Lett. 2018; 202:44-51. DOI: 10.1016/j.imlet.2018.08.001. View

14.

Majeed S, Aparnathi M, Nixon K, Venkatasubramanian V, Rahman F, Song L . Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer. Clin Cancer Res. 2022; 28(9):1966-1978. PMC: 9365348. DOI: 10.1158/1078-0432.CCR-21-0344. View

15.

Hu H, Sun S . Ubiquitin signaling in immune responses. Cell Res. 2016; 26(4):457-83. PMC: 4822134. DOI: 10.1038/cr.2016.40. View

16.

Aichem A, Kalveram B, Spinnenhirn V, Kluge K, Catone N, Johansen T . The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J Cell Sci. 2012; 125(Pt 19):4576-85. DOI: 10.1242/jcs.107789. View

17.

Ferrada M, Savic S, Ospina Cardona D, Collins J, Alessi H, Gutierrez-Rodrigues F . Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022; 140(13):1496-1506. PMC: 9523373. DOI: 10.1182/blood.2022016985. View

18.

Park H, Kim J, Baek K . Regulation of Wnt Signaling through Ubiquitination and Deubiquitination in Cancers. Int J Mol Sci. 2020; 21(11). PMC: 7311976. DOI: 10.3390/ijms21113904. View

19.

Zhang X, Linder S, Bazzaro M . Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers. Cancers (Basel). 2020; 12(4). PMC: 7226376. DOI: 10.3390/cancers12040902. View

20.

Lee P, Dodart J, Aron L, Finley L, Bronson R, Haigis M . Altered social behavior and neuronal development in mice lacking the Uba6-Use1 ubiquitin transfer system. Mol Cell. 2013; 50(2):172-84. PMC: 3640669. DOI: 10.1016/j.molcel.2013.02.014. View